Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Relacorilant: First Approval.

Drugs·2026
Same author

Rovadicitinib: First Approval.

Drugs·2026
Same author

Sonrotoclax: First Approval.

Drugs·2026
Same author

Copper Histidinate: Pediatric First Approval.

Paediatric drugs·2026
Same author

Correction: Avutometinib and Defactinib: First Approval.

Drugs·2026
Same author

Lerodalcibep: First Approval.

Drugs·2026

相关实验视频

Updated: May 26, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K

泽诺库图祖马布:首次获得批准

Hannah A Blair1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 24, 2025
PubMed
概括

泽诺库图祖马布是一种新的双特异性抗体,已被批准用于治疗晚期胰腺癌或非小细胞肺癌 (NSCLC),使用特定的基因融合. 这标志着NRG1+固体瘤患者在先前治疗中进展的患者的显著进展.

科学领域:

  • 在瘤学瘤学.
  • 分子向疗法分子向疗法
  • 药物开发 药物开发

背景情况:

  • 泽诺库图祖马布是一种IgG1双特异性抗体,向人类表皮生长因子受体 (HER) 2和HER3.
  • 它是针对由神经调节素1 (NRG1) 基因融合为特征的固体瘤开发的.
  • NRG1基因融合代表了一种特定的分子变异,在某些癌症中驱动瘤生长.

研究的目的:

  • 总结一下泽诺库图祖马布的关键发展里程碑.
  • 要突出导致其首次批准的监管途径.
  • 详细说明其针对特定高级固体瘤的适应性.

主要方法:

  • 检查曾古图祖马布的临床前和临床发展数据.
  • 对监管提交和批准流程的分析.
  • 专注于胰腺腺癌和NSCLC中NRG1基因融合的患者群体.

主要成果:

  • 泽诺库图祖马布在2024年12月4日获得了美国的首次批准.
  • 批准适用于患有晚期,不可切除或转移性胰腺腺癌或NSCLC的成年人.
  • 患者必须在先前的全身治疗后具有NRG1基因融合和疾病进展.

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.4K

相关实验视频

Last Updated: May 26, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.4K

结论:

  • 泽诺库图祖马布代表了一种新的治疗选择,用于基因定义的患者子集.
  • 这项批准标志着NRG1融合阳性癌症向治疗的里程碑.
  • 该药物为晚期胰腺癌和NSCLC提供了一种新的二线治疗策略.